Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...
A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...
Xie Qing, director of infectious diseases department at Ruijin Hospital, which is affiliated with Shanghai Jiao Tong ...
China has made significant progress in reducing mother-to-child transmission of hepatitis B, but further efforts are needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback